Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etokimab - AnaptysBio

Drug Profile

Etokimab - AnaptysBio

Alternative Names: ANB020; Anti-IL33-antibody-AnaptysBio; Anti-interleukin-33-antibody-AnaptysBio

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnaptysBio
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibodies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis; Peanut hypersensitivity; Rhinosinusitis

Most Recent Events

  • 08 Nov 2019 AnaptysBio plans a phase IIb multi-dose trial for eosinophilic Asthma
  • 05 Jun 2019 Pharmacodynamics, efficacy and adverse events data from a phase IIa in Eosinophilic asthma released by AnaptysBio
  • 28 Mar 2019 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Australia (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top